3 Einträge gefunden

1. The ACCOST-HH Trial:An investigator-initiated trial, the placebo-controlled, double-blind, multi-centre, randomized trial to assess the efficacy and safety of the antibody AdreCizumab (HAM8101) against plaCebO in SubjecTs witH cardiogenic sHock, (ACCOST-HH) in progress is discussed

   1. Skurk, Carsten
   2. Rottbauer, Wolfgang
   3. Kessler, Mirjam
   4. Akin, Ibrahim
   5. Kluge, Stefan
   6. Burdelski, Christoph
   7. Blankenberg, Stefan

   2020 - Forschungsinformationssystem des UKE
2. Prognostic impact of Interleukin-1 receptor antagonist in patients with documented coronary artery disease

   1. Schofer, Niklas
   2. Ludwig, Sebastian
   3. Rübsamen, Nicole
   4. Schnabel, Renate
   5. Lackner, Karl J
   6. Ruprecht, Hans J
   7. Bickel, Christoph

   2018 - Forschungsinformationssystem des UKE
3. Corrigendum to "Prognostic Impact of Interleukin-1 Receptor Antagonist in Patients with documented Coronary Artery Disease" [Int. J. Cardiol. 257 (2018) 24-29]

   1. Schofer, Niklas
   2. Ludwig, Sebastian
   3. Rübsamen, Nicole
   4. Schnabel, Renate
   5. Lackner, Karl J
   6. Ruprecht, Hans J
   7. Bickel, Christoph

   2018 - Forschungsinformationssystem des UKE